PMC:7228307 / 47632-47912 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"914","span":{"begin":215,"end":223},"obj":"Gene"},{"id":"915","span":{"begin":259,"end":267},"obj":"Gene"},{"id":"918","span":{"begin":96,"end":124},"obj":"Disease"},{"id":"920","span":{"begin":170,"end":175},"obj":"Mutation"},{"id":"921","span":{"begin":180,"end":185},"obj":"Mutation"}],"attributes":[{"id":"A914","pred":"tao:has_database_id","subj":"914","obj":"Gene:2214"},{"id":"A915","pred":"tao:has_database_id","subj":"915","obj":"Gene:2214"},{"id":"A918","pred":"tao:has_database_id","subj":"918","obj":"MESH:D015451"},{"id":"A920","pred":"tao:has_standard_notation","subj":"920","obj":"p.S329D"},{"id":"A921","pred":"tao:has_standard_notation","subj":"921","obj":"p.I332E"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T388","span":{"begin":14,"end":22},"obj":"Body_part"},{"id":"T389","span":{"begin":104,"end":115},"obj":"Body_part"}],"attributes":[{"id":"A388","pred":"fma_id","subj":"T388","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A389","pred":"fma_id","subj":"T389","obj":"http://purl.org/sig/ont/fma/fma62863"}],"text":"The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T84","span":{"begin":96,"end":124},"obj":"Disease"},{"id":"T85","span":{"begin":104,"end":124},"obj":"Disease"},{"id":"T86","span":{"begin":116,"end":124},"obj":"Disease"}],"attributes":[{"id":"A84","pred":"mondo_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/MONDO_0004948"},{"id":"A85","pred":"mondo_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/MONDO_0005402"},{"id":"A86","pred":"mondo_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/MONDO_0005059"}],"text":"The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T821","span":{"begin":9,"end":13},"obj":"http://purl.obolibrary.org/obo/CLO_0053432"},{"id":"T822","span":{"begin":166,"end":168},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T823","span":{"begin":215,"end":217},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T824","span":{"begin":259,"end":261},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"914","span":{"begin":215,"end":223},"obj":"Gene"},{"id":"915","span":{"begin":259,"end":267},"obj":"Gene"},{"id":"918","span":{"begin":96,"end":124},"obj":"Disease"},{"id":"920","span":{"begin":170,"end":175},"obj":"Mutation"},{"id":"921","span":{"begin":180,"end":185},"obj":"Mutation"}],"attributes":[{"id":"A914","pred":"pubann:denotes","subj":"914","obj":"Gene:2214"},{"id":"A915","pred":"pubann:denotes","subj":"915","obj":"Gene:2214"},{"id":"A918","pred":"pubann:denotes","subj":"918","obj":"MESH:D015451"},{"id":"A920","pred":"pubann:has_HGVS_notation","subj":"920","obj":"p.S329D"},{"id":"A921","pred":"pubann:has_HGVS_notation","subj":"921","obj":"p.I332E"}],"text":"The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T276","span":{"begin":0,"end":280},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele."}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T596","span":{"begin":9,"end":13},"obj":"Protein"}],"attributes":[{"id":"A596","pred":"uniprot_id","subj":"T596","obj":"https://www.uniprot.org/uniprot/Q9BRD6"},{"id":"A597","pred":"uniprot_id","subj":"T596","obj":"https://www.uniprot.org/uniprot/Q96S68"},{"id":"A598","pred":"uniprot_id","subj":"T596","obj":"https://www.uniprot.org/uniprot/Q542B2"},{"id":"A599","pred":"uniprot_id","subj":"T596","obj":"https://www.uniprot.org/uniprot/Q3LRP3"},{"id":"A600","pred":"uniprot_id","subj":"T596","obj":"https://www.uniprot.org/uniprot/P25918"},{"id":"A601","pred":"uniprot_id","subj":"T596","obj":"https://www.uniprot.org/uniprot/P25917"},{"id":"A602","pred":"uniprot_id","subj":"T596","obj":"https://www.uniprot.org/uniprot/P15391"},{"id":"A603","pred":"uniprot_id","subj":"T596","obj":"https://www.uniprot.org/uniprot/F5H635"},{"id":"A604","pred":"uniprot_id","subj":"T596","obj":"https://www.uniprot.org/uniprot/A0N0P9"}],"text":"The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T387","span":{"begin":14,"end":22},"obj":"Body_part"},{"id":"T388","span":{"begin":104,"end":115},"obj":"Body_part"}],"attributes":[{"id":"A387","pred":"fma_id","subj":"T387","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A388","pred":"fma_id","subj":"T388","obj":"http://purl.org/sig/ont/fma/fma62863"}],"text":"The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T37","span":{"begin":96,"end":124},"obj":"Disease"}],"attributes":[{"id":"A37","pred":"mondo_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/MONDO_0004948"}],"text":"The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele."}

{"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T33","span":{"begin":96,"end":124},"obj":"Phenotype"}],"attributes":[{"id":"A33","pred":"hp_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/HP_0005550"}],"text":"The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele."}

{"project":"LitCovid-sentences","denotations":[{"id":"T276","span":{"begin":0,"end":280},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T33","span":{"begin":96,"end":124},"obj":"Phenotype"}],"attributes":[{"id":"A33","pred":"hp_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/HP_0005550"}],"text":"The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele."}